Drug Profile
CP 601927
Alternative Names: CP-601,927Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antidepressants
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 10 Nov 2011 Discontinued - Phase-II for Major depressive disorder in USA (PO)
- 01 Jun 2010 Phase-II clinical trials in Major depressive disorder in USA (PO)
- 27 Jan 2010 Phase-I clinical trials in Depression in USA (PO)